{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-265499","form_type":"8-K","ticker":"MO","cik":"0000764180","company_name":"ALTRIA GROUP, INC.","filed_at":"2022-10-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.520455+00:00","generated_at":"2026-06-23T02:28:38.161826+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Altria to assign IQOS U.S. rights to PMI for $2.7B cash, effective April 2024","bullets":["Altria receives $1B immediately and $1.7B (plus 6% interest) by July 15, 2023 from PMI subsidiary Triaga.","IQOS exclusive U.S. commercialization rights assigned to PMI effective April 30, 2024.","IQOS currently unavailable in U.S. due to ITC import ban; PMI targets supply resumption in H1 2023.","Altria will record $2.7B as deferred gain in Q4 2022, recognized in earnings upon assignment.","Altria gains flexibility to invest in other smoke-free products; expects to finalize two product designs by end of 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-265499","json":"https://secwatch.observer/filing/0001193125-22-265499.json","markdown":"https://secwatch.observer/filing/0001193125-22-265499.md","text":"https://secwatch.observer/filing/0001193125-22-265499.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/764180/000119312522265499/0001193125-22-265499-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/764180/000119312522265499/d361503d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T02:28:38.161826+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}